title: Treatment of renal ANCA-associated vasculitides.
abstract: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a group of small vessel vasculitides which commonly affect the kidneys, manifesting as rapidly progressive glomerulonephritis. In this review, we present different treatment methods (e.g. cyclophosphamide, rituximab, plasma exchange) used for remission induction and maintenance in renal AAV. We also discuss treatment options in relapsing and refractory disease and for patients with end-stage renal disease due to AAV. In addition, we enumerate the various risk factors associated with relapsing and refractory disease, quality of life impairment and decreased renal and patient survival in AAV. Finally we present information on new, potentially applicable agents which can further help modify the disease course, thereby leading to increased patient survival.
authors.affiliation: Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.
authors.forename: Olumide Olatubosun
authors.initials: OO
authors.lastname: Rowaiye
authors.affiliation: Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.
authors.forename: Mariusz
authors.initials: M
authors.lastname: Kusztal
authors.affiliation: Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland; Faculty of Dentistry, Wroclaw Medical University, Wroclaw, Poland; Fresenius Polska.
authors.forename: Wacław
authors.initials: W
authors.lastname: Weyde
authors.affiliation: Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.
authors.forename: Marian
authors.initials: M
authors.lastname: Klinger
mesh_terms: D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000150:complications / Q000188:drug therapy*; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D018450:Disease Progression; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy*; D011788:Quality of Life; D012074:Remission Induction; D000069283:Rituximab / Q000008:administration & dosage*
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D000069283:Rituximab; D003520:Cyclophosphamide